Redeye comments on Ultimovacs’ Q1 report; with patient recruitment for the company’s phase II trials...
Redeye comments on Cyxone’s Q1 report and potential impact on the new strategy.
Q1 sales -15% vs. ABG, EBITA margin 3% vs. ABG 12% Consensus estimates to come down Conference call ...
Redeye changes our short-term estimates slightly because of a better outcome than expected in the fi...
Adj. EBITA SEK 13.5m, 22% above ABGSCe Estimates up ~10% on est.
Sales +39% y-o-y, +12% vs. ABGSCe EBITDA SEK 4.0m +44% vs.
6% sales and 20% EBITA beat vs ABGSCe in Q1 Guidance intact: “2022 adj.
Bonesupport uppvisade återigen stark tillväxt på den amerikanska marknaden.
Odinwell har nått avgörande delmål i teknikutvecklingen och valideringsstudier ska inledas.
Redeye remains optimistic about Image Systems’ prospects following last year’s turn-around in RemaSa...
Ferronordic delivered a decent Q1 report with earnings significantly stronger than expected (EBIT 41...
Guidance and estimates down on production issues One step forward on Block 56 Discounts long-term...
Company activities Studentbostäder I Norden has a vision to provide sustainable housing for student...
Redeye comments on Isofol’s Q1 2022 report, with the company closing in on critical AGENT top-line d...
Kostnadsuppgång i Q1 Nettoomsättningen minskade under Q1 2022 till 0,5 mkr (9,9), där skillnaden huv...
Stegar framåt med nya samarbeten Intäkterna för Q1 uppgick till 4 mkr (varav omsättning 4 mkr) som h...
Q1 i linje med våra estimat Omsättningen i kvartalet uppgick till EUR 12,7m vilket motsvarar en till...
Redeye comments on Qleanair’s Q1-figures with organic sales growth of 1.
Redeye comments on NeoDynamics’ Q1 report and notes several important key activities carried out in ...
Q1 starts off the year at full steam Positive revisions from profitability surprise SiteBase is fina...
